Schedule 13G ownership disclosure
BIOCRYST PHARMACEUTICALS INC
Common Stock · CUSIP: 09058V103
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deerfield Mgmt, L.P.
Shares: 14,341,000.00 · Class: 6.81%
- Deerfield Management Company, L.P.
Shares: 14,341,000.00 · Class: 6.81%
- Deerfield Partners, L.P.
Shares: 14,341,000.00 · Class: 6.81%
- James E. Flynn
Shares: 14,341,000.00 · Class: 6.81%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193805-26-000127
- Form type
- SCHEDULE 13G/A
- Filer
- BIOCRYST PHARMACEUTICALS INC
- CIK
- CIK 882796
- Filed
- Feb 12, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership